Novo Nordisk A/S (NYSE:NVO) Receives $144.50 Average PT from Analysts

Novo Nordisk A/S (NYSE:NVO - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $144.50.

NVO has been the subject of several research analyst reports. StockNews.com raised Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday, November 1st. Cantor Fitzgerald reissued an "overweight" rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, BMO Capital Markets lowered their target price on Novo Nordisk A/S from $160.00 to $156.00 and set an "outperform" rating for the company in a research note on Thursday, October 17th.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock traded up $2.82 during midday trading on Tuesday, hitting $102.63. 5,353,914 shares of the company's stock were exchanged, compared to its average volume of 4,480,748. Novo Nordisk A/S has a 52-week low of $94.73 and a 52-week high of $148.15. The stock has a 50-day moving average price of $117.94 and a two-hundred day moving average price of $129.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The company has a market cap of $460.56 billion, a P/E ratio of 32.30, a PEG ratio of 1.31 and a beta of 0.42.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Advisor OS LLC grew its stake in shares of Novo Nordisk A/S by 0.6% in the 2nd quarter. Advisor OS LLC now owns 13,972 shares of the company's stock worth $1,994,000 after buying an additional 82 shares during the last quarter. Cascade Financial Partners LLC grew its stake in shares of Novo Nordisk A/S by 2.3% in the 2nd quarter. Cascade Financial Partners LLC now owns 3,801 shares of the company's stock worth $543,000 after buying an additional 84 shares during the last quarter. Novare Capital Management LLC grew its stake in shares of Novo Nordisk A/S by 3.2% in the 3rd quarter. Novare Capital Management LLC now owns 2,727 shares of the company's stock worth $325,000 after buying an additional 85 shares during the last quarter. AA Financial Advisors LLC grew its stake in shares of Novo Nordisk A/S by 3.2% in the 2nd quarter. AA Financial Advisors LLC now owns 2,805 shares of the company's stock worth $400,000 after buying an additional 86 shares during the last quarter. Finally, Steel Grove Capital Advisors LLC grew its stake in shares of Novo Nordisk A/S by 2.3% in the 2nd quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company's stock worth $541,000 after buying an additional 86 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.